EA202192294A1 - Антитела к trem2 и способы их применения - Google Patents
Антитела к trem2 и способы их примененияInfo
- Publication number
- EA202192294A1 EA202192294A1 EA202192294A EA202192294A EA202192294A1 EA 202192294 A1 EA202192294 A1 EA 202192294A1 EA 202192294 A EA202192294 A EA 202192294A EA 202192294 A EA202192294 A EA 202192294A EA 202192294 A1 EA202192294 A1 EA 202192294A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- trem2
- antibodies
- methods
- application
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
В одном аспекте представлены антитела, которые специфически связываются с человеческим триггерным рецептором, экспрессируемым на миелоидных клетках 2 (TREM2). В некоторых вариантах осуществления антитело снижает уровни растворимого TREM2 (sTREM2). В некоторых вариантах осуществления антитело усиливает активность TREM2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808141P | 2019-02-20 | 2019-02-20 | |
| PCT/US2020/019093 WO2020172450A1 (en) | 2019-02-20 | 2020-02-20 | Anti-trem2 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192294A1 true EA202192294A1 (ru) | 2021-12-24 |
Family
ID=69844940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192294A EA202192294A1 (ru) | 2019-02-20 | 2020-02-20 | Антитела к trem2 и способы их применения |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20220073609A1 (ru) |
| EP (1) | EP3927743A1 (ru) |
| JP (1) | JP2022520868A (ru) |
| KR (1) | KR20210135518A (ru) |
| CN (1) | CN113614110A (ru) |
| AR (1) | AR118144A1 (ru) |
| AU (1) | AU2020226754A1 (ru) |
| BR (1) | BR112021015656A2 (ru) |
| CA (1) | CA3130086A1 (ru) |
| CL (1) | CL2021002206A1 (ru) |
| CO (1) | CO2021012230A2 (ru) |
| EA (1) | EA202192294A1 (ru) |
| EC (1) | ECSP21069105A (ru) |
| IL (1) | IL285651A (ru) |
| MA (1) | MA55025A (ru) |
| MX (1) | MX2021009722A (ru) |
| PE (1) | PE20211979A1 (ru) |
| SG (1) | SG11202108734VA (ru) |
| TW (1) | TW202045543A (ru) |
| WO (2) | WO2020172457A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN115279790A (zh) | 2020-01-13 | 2022-11-01 | 戴纳立制药公司 | 抗trem2抗体和其使用方法 |
| EP4337317A1 (en) * | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Agonists of trem2 |
| WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
| WO2023192288A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| SG10201913611QA (en) * | 2014-08-08 | 2020-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CN114751989A (zh) * | 2015-03-31 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 包含三聚体tnf家族配体的抗原结合分子 |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| SG10201912150TA (en) * | 2015-10-06 | 2020-02-27 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| TWI811229B (zh) | 2017-08-03 | 2023-08-11 | 美商阿列克特有限責任公司 | 抗trem2抗體及其使用方法 |
-
2020
- 2020-02-20 JP JP2021548668A patent/JP2022520868A/ja active Pending
- 2020-02-20 CN CN202080015804.2A patent/CN113614110A/zh active Pending
- 2020-02-20 WO PCT/US2020/019104 patent/WO2020172457A1/en active Application Filing
- 2020-02-20 MX MX2021009722A patent/MX2021009722A/es unknown
- 2020-02-20 CA CA3130086A patent/CA3130086A1/en active Pending
- 2020-02-20 AR ARP200100461A patent/AR118144A1/es unknown
- 2020-02-20 BR BR112021015656-9A patent/BR112021015656A2/pt unknown
- 2020-02-20 KR KR1020217028927A patent/KR20210135518A/ko unknown
- 2020-02-20 PE PE2021001367A patent/PE20211979A1/es unknown
- 2020-02-20 EA EA202192294A patent/EA202192294A1/ru unknown
- 2020-02-20 MA MA055025A patent/MA55025A/fr unknown
- 2020-02-20 WO PCT/US2020/019093 patent/WO2020172450A1/en unknown
- 2020-02-20 SG SG11202108734VA patent/SG11202108734VA/en unknown
- 2020-02-20 EP EP20711737.5A patent/EP3927743A1/en active Pending
- 2020-02-20 AU AU2020226754A patent/AU2020226754A1/en active Pending
- 2020-02-20 TW TW109105560A patent/TW202045543A/zh unknown
-
2021
- 2021-08-16 US US17/403,406 patent/US20220073609A1/en active Pending
- 2021-08-16 IL IL285651A patent/IL285651A/en unknown
- 2021-08-16 US US17/402,986 patent/US20220119522A1/en active Pending
- 2021-08-18 CL CL2021002206A patent/CL2021002206A1/es unknown
- 2021-09-17 EC ECSENADI202169105A patent/ECSP21069105A/es unknown
- 2021-09-17 CO CONC2021/0012230A patent/CO2021012230A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020172450A1 (en) | 2020-08-27 |
| AU2020226754A1 (en) | 2021-09-16 |
| MA55025A (fr) | 2021-12-29 |
| BR112021015656A2 (pt) | 2021-10-05 |
| CL2021002206A1 (es) | 2022-04-22 |
| CA3130086A1 (en) | 2020-08-27 |
| CN113614110A (zh) | 2021-11-05 |
| US20220073609A1 (en) | 2022-03-10 |
| TW202045543A (zh) | 2020-12-16 |
| WO2020172457A1 (en) | 2020-08-27 |
| MX2021009722A (es) | 2021-09-14 |
| EP3927743A1 (en) | 2021-12-29 |
| ECSP21069105A (es) | 2021-11-18 |
| JP2022520868A (ja) | 2022-04-01 |
| IL285651A (en) | 2021-09-30 |
| SG11202108734VA (en) | 2021-09-29 |
| PE20211979A1 (es) | 2021-10-05 |
| AR118144A1 (es) | 2021-09-22 |
| US20220119522A1 (en) | 2022-04-21 |
| CO2021012230A2 (es) | 2021-09-30 |
| KR20210135518A (ko) | 2021-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202192294A1 (ru) | Антитела к trem2 и способы их применения | |
| MX2022008582A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
| EA202091339A1 (ru) | Антитела против cd47 и их применение для лечения онкологических заболеваний | |
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| PH12020500368A1 (en) | B7-h4 antibodies and methods of use thereof | |
| MY201526A (en) | Anti-trem2 antibodies and methods of use thereof | |
| AR057807A1 (es) | Formulaciones de anticuerpo anti-cd3 | |
| EA201990171A1 (ru) | Биспецифичное антитело против egfr и против cd3 и его применения | |
| MY189159A (en) | Multispecific antigen-binding molecules and uses thereof | |
| PA8645301A1 (es) | Anticuerpo anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| AR065083A1 (es) | Hepcidina, antagonistas de la hepcidina y metodos de uso | |
| ATE476992T1 (de) | Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper | |
| EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
| EA202190608A1 (ru) | Однодоменные анти-bcma антитела и их применение | |
| PH12019502302A1 (en) | Anti-pd-l1 antibody and use thereof | |
| PH12021550255A1 (en) | Anti-npr1 antibodies and uses thereof | |
| MX2021004779A (es) | Anticuerpos cd47 novedosos y metodos para usarlos. | |
| UA94211C2 (ru) | Выделенное полностью человеческое моноклональное cd3 антитело | |
| CL2022001886A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| MX2022007231A (es) | Anticuerpos anti-mertk y metodos de uso de los mismos. | |
| ZA202205927B (en) | Anti-yellow fever virus antibodies, and methods of their generation and use | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
| EA200970884A1 (ru) | Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18 |